Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension and Open Label Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT07161999 is registered in ClinicalTrials.gov with Coya Therapeutics as lead sponsor.

NCT NCT07161999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07161999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension and Open Label Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
Coya Therapeutics
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
October 1, 2025
Completion date
October 31, 2027
Enrollment
120 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)